Print this article

Avecia and Nitto Denko – Providing support for the future of oligonucleotides



April 1st 2012 marked the moment of change when Avecia Biotechnology Inc., a leader in oligonucleotide contract manufacturing, became NITTO DENKO Avecia Inc. Avecia and Nitto Denko share a commitment to the future of the oligonucleotide market; they provide both products and services designed to facilitate the evolution of oligonucleotide technologies, and offer a dependable resource as oligo therapeutics progress from pre-clinical and clinical phases through to commercial launch and supply.
One year after the acquisition of Avecia by Nitto Denko, the contract manufacturing organization (CMO) has continued to u